ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

10897	Companies
237410	Keywords
166346	Articles
127499	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/20/2025 at 19:30, 1 year 2 months ago

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics reaffirms commitment to transparent and serene General Meeting in compliance with market rules, providing 'Questions and Answers' document for shareholders

Shareholders Transparency General Meeting OSE Immunotherapeutics Market Rules
BRIEF

published on 06/19/2025 at 15:58, 1 year 2 months ago

Strategic change within OSE Immunotherapeutics

Board Of Directors General Meeting Crossing Thresholds OSE Immunotherapeutics Shareholders' Agreement
BRIEF

published on 04/30/2025 at 07:35, 1 year 4 months ago

OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025

Immuno-oncology Personalized Treatment Immune Checkpoint Blockade Gene Expression Signature Cancer Prediction
PRESS RELEASE

published on 04/30/2025 at 07:30, 1 year 4 months ago

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
OSE Immunotherapeutics and Léon Bérard Cancer Center present a new gene expression signature for predicting clinical response to immune checkpoint at AACR Annual Meeting 2025

AACR Annual Meeting OSE Immunotherapeutics Gene Expression Signature Léon Bérard Cancer Center Clinical Response Prediction
BRIEF

published on 04/09/2025 at 07:35, 1 year 4 months ago

OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025

Ulcerative Colitis OSE Immunotherapeutics Lusvertikimab Phase 2 Extension DDW 2025
PRESS RELEASE

published on 04/09/2025 at 07:30, 1 year 4 months ago

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics to present new data on Lusvertikimab's long-term benefits and safety in ulcerative colitis at DDW 2025, showcasing potential in autoimmune diseases

Ulcerative Colitis Immuno-oncology Inflammatory Diseases OSE Immunotherapeutics Lusvertikimab
BRIEF

published on 11/04/2024 at 07:35, 1 year 9 months ago

OSE Immunotherapeutics Reveals Promising Phase 2 Results for Ulcerative Colitis Treatment

Ulcerative Colitis Phase 2 Study OSE Immunotherapeutics Clinical Results Lusvertikimab
PRESS RELEASE

published on 11/04/2024 at 07:30, 1 year 9 months ago

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics reports positive results from Phase 2 study of Lusvertikimab for Ulcerative Colitis treatment. Primary endpoint met with high clinical and endoscopic remission rates

Positive Results Phase 2 Study OSE Immunotherapeutics Lusvertikimab Ulcerative Colitis Treatment
BRIEF

published on 09/10/2024 at 07:35, 1 year 11 months ago

OSE Immunotherapeutics Launches Phase 3 Study for Tedopi® in Lung Cancer

NSCLC Immunotherapy Phase 3 Trial Cancer Vaccine Global Launch
PRESS RELEASE

published on 09/10/2024 at 07:30, 1 year 11 months ago

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
OSE Immunotherapeutics launches international Phase 3 trial 'Artemia' of cancer vaccine Tedopi® in second-line NSCLC treatment, aiming for regulatory approval in Europe and North America

NSCLC Phase 3 Trial OSE Immunotherapeutics Artemia Tedopi

Accesswire

Published on 08/29/2026 at 05:15, 1 day 11 hours ago

Norsemont Announces Restatement of Financial Statements
Published on 08/29/2026 at 03:20, 1 day 13 hours ago

BEACN Announces Financial Results for the Second Quarter of 2026
Published on 08/29/2026 at 01:15, 1 day 15 hours ago

Gamma Resources Announces Increase in Private Placement to $1,750,000 and Closing of First Tranche at $872,500
Published on 08/29/2026 at 01:00, 1 day 16 hours ago

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Published on 08/28/2026 at 23:00, 1 day 18 hours ago

Guanajuato Silver Grants Stock Options to Officer

View all ACCESSWIRE

EQS Group

Published on 08/29/2026 at 04:05, 1 day 13 hours ago

INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces
Published on 08/28/2026 at 20:49, 1 day 20 hours ago

Publication pursuant to Article 5(1)(b) and (3) of Regulation (EU) No. 596/2014 and Article 2(2) and (3) of the Commission Delegated Regulation (EU) No. 2016/1052 - Final Announcement
Published on 08/28/2026 at 20:42, 1 day 20 hours ago

Aroundtown SA: Release of a capital market information
Published on 08/28/2026 at 19:10, 1 day 22 hours ago

Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Published on 08/28/2026 at 18:01, 1 day 23 hours ago

CPI Europe announces unaudited results for the first half of 2026

Les Echos

Published on 08/28/2026 at 06:55, 2 days 10 hours ago

Recticel Accelerates Profitable Growth
Published on 08/26/2026 at 18:02, 3 days 23 hours ago

Altareit: Altarea press release regarding the Primonial matter
Published on 08/26/2026 at 18:00, 3 days 23 hours ago

Altarea: Comprehensive settlement agreement reached, ending the dispute between Altarea and the shareholders of the Praemia group (formerly Primonial group)
Published on 08/26/2026 at 17:40, 3 days 23 hours ago

First half 2026 results
Published on 08/25/2026 at 17:45, 4 days 23 hours ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE